TIMP1 Overexpression

CI-VAR-00003137Explore in graph →CIViC 377

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm2
TIMP1 Overexpression	Fulvestrant	Predictive	D	Supports Resistance	2	accepted	EID901 TIMP1 overexpression was associated with resistance to fulvestrant in breast cancer cell lines. PMID 23881388 · Bjerre et al., 2013 · Open in CIViC	civic
TIMP1 Overexpression	Paclitaxel	Predictive	B	Supports Resistance	2	accepted	EID927 High expression of TIMP-1 was assessed by IHC in 99 primary breast cancers that had not spread beyond the breast after 6 postoperative courses of paclitaxel-based chemotherapy. High TIMP1 levels were … (full text at CIViC) PMID 22544540 · Zhu et al., 2012 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.